UNSPSC 51172323: Glucarpidase

This classification denotes an enzyme replacement preparation, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2GFP9BJD79. European Medicines Agency schedules Glucarpidase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25203. Glucarpidase generally arises in the molecular formula 4ZN. The term GLUCARPIDASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations schedule glucarpidase under HS 35079090 and SITC 51691.

As of Q4 2014, GLUCARPIDASE remains the US FDA Preferred Term for this commodity. Glucarpidase bears US NLM identifiers UMLS ID C0007072 and NCI Concept Code C346. SMILES: none.

UNSPSC 51172323 Glucarpidase, a Commodity code, does not align with recent state and local procurement activity. The three most recent opportunities tagged to this code involve offender drug testing services (Collin County, Texas), pharmacy benefit management infrastructure (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals distribution (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations specifically procure glucarpidase or chemotherapy supportive-care pharmaceuticals. The code shows little relevant recent activity, and the tagged opportunities appear to reflect misclassification rather than genuine glucarpidase procurement demand in state and local markets.

The Collin County Community Supervision and Corrections Department RFP 2026-327, due July 23, 2026, focuses on offender specimen collection and drug testing using immunoassay and LC/MS/MS or GC/MS confirmation methodologies, with an estimated contract value of $600,000 over two years. The Texas HHS Commission RFI HHS0017013 seeks vendor information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802, due March 26, 2026, establishes contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers. None of these procurements targets specialty oncology supportive care or glucarpidase supply, suggesting the code's current assignment to these opportunities does not reflect actual commodity demand.